Tecuro AG


Main Business:

Tecuro proposes a novel product for female patients suffering from recurrent urinary tract infections: an effective disinfectant solution with panty liners that act as an antimicrobial barrier.

Date Founded:

Q2 2010

Date SymbioSwiss Entered:

Q3 2013

SymbioSwiss Role:

SymbioSwiss is the lead investor and has been involved in the due diligence.


Jean-Jacques Becciolini


Luzern, Switzerland

Development Stage:

Early stage. Product fine tuning. Pre-clinical trial preparation.

Current Funding:

Second round completed

Positive Potential:

Market size is around 1,6 billion CHF. Target patients: 14 m women suffering from recurrent infection.

URL: http://tecuro.ch/wp1/


Follow Us
facebook person linkedin twitter
Contact Us
* all fields are required